SEC Filings
Revvity Targets Above-Market Growth And $5 Billion For Deals, Buybacks And Dividends
The research-tools and diagnostics company pairs its growth ambitions with margin targets after cutting staff and facilities space.
SEC Filings
The research-tools and diagnostics company pairs its growth ambitions with margin targets after cutting staff and facilities space.
SEC Filings
December trial results will determine whether the company pursues its planned U.S. drug-approval application in mid-2027.
SEC Filings
William Twomey's package includes a $450,000 salary and a planned $500,000 stock grant as SiriusXM prepares for new leadership.
SEC Filings
The Japanese banking group estimated a ¥200.00 annual dividend per ordinary share, up from ¥145.00 in fiscal 2025.
SEC Filings
Discounted buybacks cancelled debt, but a separate warrant offer leaves the next repayment bill dependent on holders' choices.
SEC Filings
Twelve participants stopped intravenous glucose entirely; Rezolute expects the completed-study analysis by mid-December 2026.
SEC Filings
The bonds pay 4.125% annually, while debt Moody’s may repay carries a 1.75% rate and comes due in 2027.
SEC Filings
AIRO controls the price, timing and size of sales, which can start only after its registration statement becomes effective.
SEC Filings
Eligible employees can defer all annual bonuses, but plan balances remain exposed to creditors if the company becomes insolvent.
SEC Filings
The proposed single dose covers previously vaccinated people aged 10 and older, targeting another period of increased meningitis B risk.
SEC Filings
Research spending rose as the company advanced its lead drug, with initial late-stage dermatitis results expected in summer 2028.
SEC Filings
The units combine future stock purchases with senior-note interests and carry annual distributions of 8.625%.